注射用鼠神经生长因子联合奥拉西坦治疗高血压脑出血的临床研究  

Clinical Study of Mouse Nerve Growth Factor for Injection Combined with Oxiracetam in the Treatment of Hypertensive Cerebral Hemorrhage

作　　者：于海永 张颖 师仰宏[2] YU Haiyong;ZHANG Ying;SHI Yanghong(Dept. of Neurology, Chaoyang the Second Hospital, Liaoning Chaoyang 122000, China;Dept. of Neurology, the First Hospital of Yulin, Shaanxi Yulin 719000, China)

机构地区：[1]朝阳市第二医院神经内科,辽宁朝阳122000 [2]榆林市第一医院神经内科,陕西榆林719000

出　　处：《中国医院用药评价与分析》2020年第8期960-964,共5页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨注射用鼠神经生长因子联合奥拉西坦治疗高血压脑出血(hypertensive cerebral hemorrhage,HCH)的临床效果。方法:选取2017年10月至2019年1月朝阳市第二医院收治的HCH患者92例,采用简单随机数字表法将其分为观察组(n=46)和对照组(n=46)。对照组患者给予奥拉西坦治疗,观察组患者在此基础上加用注射用鼠神经生长因子辅助治疗,两组患者均治疗21 d。治疗结束后,对两组患者的临床疗效进行评估;并于治疗前后测评两组患者神经功能缺损程度及日常生活活动能力,检测血清脑损伤生物标志物、炎症因子及氧化应激指标水平;同时观察两组患者用药期间不良反应发生情况。结果:观察组患者的总有效率为93.48%(43/46),与对照组的76.09%(35/46)相比明显升高,差异有统计学意义(P<0.05)。两组患者治疗后美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS)评分均较治疗前明显降低,Barthel指数(BI)评分明显升高;治疗后,观察组患者NIHSS评分较对照组同期明显更低,而BI评分明显更高,差异均有统计学意义(P<0.05)。两组患者治疗后血清脑损伤标志物(神经元特异性烯醇化酶、S100β蛋白)及相关炎症因子(白细胞介素8、肿瘤坏死因子α及超敏C反应蛋白)水平均较治疗前明显降低(P<0.05),而观察组患者降低更显著,差异均有统计学意义(P<0.05)。两组患者治疗后血清超氧化物歧化酶(SOD)水平均较治疗前明显升高,血清丙二醛(MDA)、脂质过氧化物(LPO)含量明显降低;且治疗后,观察组患者血清SOD水平明显高于对照组同期,血清MDA、LPO含量则明显更低,差异均有统计学意义(P<0.05)。观察组患者不良反应发生率为15.22%(7/46),与对照组的17.39%(8/46)比较,差异无统计学意义(P>0.05)。结论:注射用鼠神经生长因子联合奥拉西坦治疗HCH可能通过下调患者相关炎症因子表达水平、纠正机体氧�OBJECTIVE:To investigate the clinical effects of mouse nerve growth factor for injection combined with oxiracetam in the treatment of hypertensive cerebral hemorrhage(HCH).METHODS:Totally 92 patients with HCH admitted into Chaoyang the Second Hospital from Oct.2017 to Jan.2019 were extracted to be divided into the observation group(n=46)and the control group(n=46)via the random number table.The control group was treated with oxiracetam,while the observation group received mouse nerve growth factor for injection.Patients in both groups were treated for 21 d.After treatment,the clinical efficacy of two groups was evaluated.The degree of neurological impairment and activities of daily living were evaluated before and after treatment,and the levels of serum brain injury biomarkers,inflammatory factors and oxidative stress indicators were detected.Meanwhile,the adverse drug reactions was observed in two groups.RESULTS:The total effective rate of the observation group was 93.48%(43/46),significantly higher than that of the control group 76.09%(35/46),with statistically significant difference(P<0.05).After treatment,the national institutes of health stroke scale(NIHSS)scores of both groups were significantly lower and Barthel Index(BI)score was significantly higher than that before treatment;after treatment,the NIHSS score of the observation group was significantly lower than that of the control group,while the BI score was significantly higher than that of the control group,with statistically significant differences(P<0.05).After treatment,the levels of serum brain injury biomarkers[neuron specific enolase(NSE),S100βprotein]and related inflammatory factors[interleukin(IL)-8,tumor necrosis factor(TNF)-α,hypersensitive C-reactive protein(hs-CRP)]in both groups were significantly lower than those before treatment,the observation group was significantly lower than the control group,with statistically significant differences(P<0.05).After treatment,the levels of serum superoxide dismutase(SOD)increased significantly in bo

关 键 词：注射用鼠神经生长因子 奥拉西坦 高血压脑出血 炎症反应 氧化应激 脑损伤标志物 

分 类 号：R977[医药卫生—药品]